Judith K Wolf

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
    John J Kavanagh
    Telik, Inc, Palo Alto, CA, USA
    J Hematol Oncol 3:9. 2010
  2. ncbi A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer
    Judith K Wolf
    Department of Gynecologic Oncology, Unit 1362, The University of Texas M D Anderson Cancer Center, 1155 Herman Pressler, Houston, TX 77030, USA
    Gynecol Oncol 102:468-74. 2006
  3. ncbi Innovations in understanding the biology of cervical cancer
    Judith K Wolf
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2064-9. 2003
  4. ncbi Gene therapy for ovarian cancer (review)
    Judith K Wolf
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 440, Houston, TX 77030, USA
    Int J Oncol 21:461-8. 2002
  5. ncbi A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer
    Judith K Wolf
    The Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Gynecol Oncol 94:442-8. 2004
  6. ncbi Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary
    David R Crotzer
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 105:404-8. 2007
  7. ncbi Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial
    Jubilee Brown
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4973-9. 2010
  8. ncbi In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines
    Anjali Gaikwad
    Department of Gynecologic Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    J Oncol Pharm Pract 15:35-44. 2009
  9. ncbi Therapeutic Targeting of ATP7B in Ovarian Carcinoma
    Lingegowda S Mangala
    Departments of Gynecologic Oncology, Experimental Therapeutics, and Cancer Biology, The University of Texas M D Anderson Cancer Center, USA
    Clin Cancer Res 15:3770-80. 2009
  10. ncbi An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines
    Judith A Smith
    Department of Gynecologic Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Gynecol Oncol 98:141-5. 2005

Detail Information

Publications46

  1. ncbi Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
    John J Kavanagh
    Telik, Inc, Palo Alto, CA, USA
    J Hematol Oncol 3:9. 2010
    ..The primary endpoints were objective response rate (ORR) and progression-free survival (PFS)...
  2. ncbi A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer
    Judith K Wolf
    Department of Gynecologic Oncology, Unit 1362, The University of Texas M D Anderson Cancer Center, 1155 Herman Pressler, Houston, TX 77030, USA
    Gynecol Oncol 102:468-74. 2006
    ..To determine the efficacy, toxicity, and quality of life of capecitabine (Xeloda), an oral 5-fluorouracil derivative, in patients with chemorefractory recurrent mullerian cancers...
  3. ncbi Innovations in understanding the biology of cervical cancer
    Judith K Wolf
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2064-9. 2003
    ..Identification of molecular changes in cervical cancer and knowledge about the importance of HPV infection in cervical cancer can lead to new therapies to treat existing cervical cancer and, in the long term, prevent the disease...
  4. ncbi Gene therapy for ovarian cancer (review)
    Judith K Wolf
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 440, Houston, TX 77030, USA
    Int J Oncol 21:461-8. 2002
    ..Gene therapy research presents unique opportunities for extending the spectrum of ovarian cancer treatment possibilities, either alone or in combination with conventional chemotherapy regimens...
  5. ncbi A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer
    Judith K Wolf
    The Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Gynecol Oncol 94:442-8. 2004
    ..This phase I study was designed as a toxicity study of multiple dosing of Adp53 administered by intraperitoneal (IP) delivery to patients with ovarian cancer...
  6. ncbi Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary
    David R Crotzer
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 105:404-8. 2007
    ..The purpose of this study was to review our experience with recurrent clear cell carcinoma of the ovary to evaluate its responsiveness to systemic cytotoxic and hormonal agents...
  7. ncbi Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial
    Jubilee Brown
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4973-9. 2010
    ..Because the combination of gemcitabine and cisplatin demonstrated synergism in preclinical studies, the authors attempted to determine the efficacy and toxicity of this combination in women with advanced or recurrent endometrial cancer...
  8. ncbi In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines
    Anjali Gaikwad
    Department of Gynecologic Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    J Oncol Pharm Pract 15:35-44. 2009
    ..In addition, the effect of gefitinib on the expression of ATP-binding cassette (ABC) transport proteins was evaluated...
  9. ncbi Therapeutic Targeting of ATP7B in Ovarian Carcinoma
    Lingegowda S Mangala
    Departments of Gynecologic Oncology, Experimental Therapeutics, and Cancer Biology, The University of Texas M D Anderson Cancer Center, USA
    Clin Cancer Res 15:3770-80. 2009
    ..Here, we examined the biological mechanisms and therapeutic potential of targeting a critical platinum resistance gene, ATP7B, using both in vitro and in vivo models...
  10. ncbi An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines
    Judith A Smith
    Department of Gynecologic Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Gynecol Oncol 98:141-5. 2005
    ..The objectives of this study were to determine the optimum schedule for combination of taxane and platinum agents in human ovarian carcinoma cell lines...
  11. ncbi Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers
    Robert L Coleman
    Department of Gynecologic Oncology, Pathology, and Gynecologic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 101:126-31. 2006
    ..To evaluate the efficacy and tolerability of imatinib mesylate (Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) in patients with recurrent ovarian and primary peritoneal cancer...
  12. ncbi Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines
    Judith A Smith
    Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Gynecol Oncol 103:518-22. 2006
    ..To evaluate the mechanism that gemcitabine modulates cisplatin drug resistance in endometrial cancer cell lines...
  13. ncbi In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines
    Judith A Smith
    Department of Gynecologic Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, P O Box 301439 UNIT 1362, Houston, TX 77230 1439, USA
    Cancer Chemother Pharmacol 62:51-8. 2008
    ..In addition, the effect of gefitinib on the expression of ATP-binding cassette (ABC) transport proteins was evaluated...
  14. ncbi Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer
    Janos L Tanyi
    Departments of Molecular Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:3534-45. 2003
    ..Thus, the LPA-rich environment of the ovarian cancer cell in vivo and the subsequent effects of cellular pathophysiology may be a consequence of both increased LPA production and decreased LPA metabolism by ovarian cancer cells...
  15. ncbi BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas
    Kwong Kwok Wong
    Departments of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Pathol 177:1611-7. 2010
    ..In addition, advanced-stage, low-grade carcinoma patients with BRAF or KRAS mutation have a better apparent clinical outcome. However, further investigation is needed...
  16. ncbi A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer
    Kathleen M Schmeler
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Gynecol Oncol 113:210-5. 2009
    ....
  17. ncbi PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas
    Celestine S Tung
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 22:1243-50. 2009
    ....
  18. ncbi Robotic radical parametrectomy and pelvic lymphadenectomy in patients with invasive cervical cancer
    Pedro T Ramirez
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Gynecol Oncol 111:18-21. 2008
    ..The goal of this study is to report on the safety and feasibility of robotic radical parametrectomy...
  19. ncbi A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary
    David R Crotzer
    The University of Texas M D Anderson Cancer Center, Department of Gynecologic Oncology, Unit 1362, P O Box 301439, Houston, TX 77230 1439, USA
    Gynecol Oncol 105:399-403. 2007
    ..To evaluate the efficacy and toxicity of cisplatin and ifosfamide in the treatment of patients with malignant mixed mesodermal tumor (MMMT) of the ovary...
  20. ncbi Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix
    Alfred D Jenkins
    Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 440, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Gynecol Oncol 97:840-4. 2005
    ..Although capecitabine is a well-tolerated regimen, as a single agent, it offers minimal benefit in a poor-prognosis cervical cancer population...
  21. ncbi Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model
    Jenifer M Saucier
    Department of Gynecologic Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Oncol Pharm Pract 13:39-45. 2007
    ....
  22. ncbi Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
    Siqing Fu
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1661-9. 2011
    ..A phase 1b-2a clinical trial of this sequential combination of azacitidine and carboplatin was initiated in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer...
  23. ncbi The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer
    Erin R King
    Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Am J Surg Pathol 35:904-12. 2011
    ..The progression of SBOT to LG serous ovarian carcinoma may involve the dedifferentiation of ciliated cells. AGR3 could serve as a prognostic marker for survival in patients with LG and HG serous ovarian carcinomas...
  24. ncbi An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines
    Judith A Smith
    Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Gynecol Oncol 92:314-9. 2004
    ..To determine the cytotoxic activity of gemcitabine on a panel of endometrial cancer cell lines and to determine if the addition of platinum agents enhanced this activity...
  25. ncbi Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer
    Janos L Tanyi
    Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas 77230 1439, USA
    Gynecol Oncol 114:219-24. 2009
    ..We sought to characterize the efficacy and adverse-effect profile of PLD in different doses and to evaluate predictive factors of palmar-plantar erythrodysesthesia (PPE)...
  26. ncbi Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer
    Diane C Bodurka
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 21:291-7. 2003
    ..To evaluate the efficacy and toxicity of irinotecan in patients with metastatic platinum-resistant or platinum-refractory epithelial ovarian cancer or primary peritoneal cancer...
  27. ncbi Overexpression of kallikrein 10 in epithelial ovarian carcinomas
    Hyun S Shvartsman
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Gynecol Oncol 90:44-50. 2003
    ..We investigated whether KLK10 and its related protein, hK10, might serve as equally accurate markers for ovarian carcinoma...
  28. ncbi A novel hTERT promoter-driven E1A therapeutic for ovarian cancer
    Xiaoming Xie
    Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, Houston, Texas 77030, USA
    Mol Cancer Ther 8:2375-82. 2009
    ..v. delivery of T-VISA-E1A:liposomal nanoparticles, suggesting a promising role of T-VISA-E1A for ovarian cancer treatment under a gene therapy setting...
  29. ncbi Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer
    Charlotte C Sun
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Unit 440, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA
    Support Care Cancer 13:219-27. 2005
    ..Selection of second- or third-line chemotherapy ultimately depends on patient preferences for different side effects. To better understand this process, we evaluated preferences and symptom distress in patients with ovarian cancer...
  30. ncbi Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230-1439, USA
    Expert Opin Pharmacother 6:1269-75. 2005
  31. ncbi Transduction of adenovirus-mediated wild-type p53 after radiotherapy in human cervical cancer cells
    Julie J Huh
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Gynecol Oncol 89:243-50. 2003
    ..CONCLUSION: Combining radiotherapy with Adp53 infection increases the inhibition of growth of cervical cancer cells in vitro. This combination treatment has the potential of increasing efficacy and of therapy...
  32. ncbi The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer
    Janos L Tanyi
    Department of Molecular Therapeutics, University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 63:1073-82. 2003
    ..Thus genetic or pharmacological manipulation of LPA metabolism, receptor activation, or downstream signaling is an attractive approach for therapy of ovarian cancer...
  33. ncbi Vacuum-assisted closure in the treatment of gynecologic oncology wound failures
    Veronica L Schimp
    Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 92:586-91. 2004
    ..Our experience indicates that this is a safe method to treat complex wound failures in gynecologic oncology patients...
  34. ncbi Ovarian and extraovarian endometriosis-associated cancer
    Susan C Modesitt
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Obstet Gynecol 100:788-95. 2002
    ..To determine clinical characteristics of women with endometriosis-associated intraperitoneal cancers, to assess differences based on the relationship of the cancer to the endometriosis, and to assess factors associated with survival...
  35. ncbi Fifth International Conference on Ovarian Cancer: challenges and opportunities
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Gynecol Oncol 97:916-23. 2005
    ..This paper provides a summary of the presentations given at the Fifth International Conference on Ovarian Cancer in Houston, Texas on December 1-4, 2004...
  36. ncbi Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer
    Michael Frumovitz
    Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Am J Obstet Gynecol 194:1186-93; discussion 1193-5. 2006
    ..CONCLUSION: Preoperative lymphoscintigraphy adds little value over intraoperative lymphatic mapping for sentinel lymph node identification during radical hysterectomy...
  37. ncbi Functional outcomes and complications of continent urinary diversions in patients with gynecologic malignancies
    Pedro T Ramirez
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Gynecol Oncol 85:285-91. 2002
    ..The purpose of this study was to review our experience with continent urinary diversions in patients with gynecologic malignancies and evaluate the presentation and management of early and late complications...
  38. ncbi Mentorship and productivity among gynecologic oncology fellows
    Lois M Ramondetta
    University of Texas M D Anderson Cancer Center, Department of Gynecologic Oncology, Houston, Texas 77030 4009, USA
    J Cancer Educ 18:15-9. 2003
    ..To identify factors that enable gynecologic oncology fellows to achieve goals set by the American Board of Obstetrics and Gynecology (ABOG)...
  39. ncbi A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets
    Lois M Ramondetta
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Gynecol Oncol 90:529-36. 2003
    ..The aim of this study was to determine the efficacy of cisplatin, ifosfamide, and mesna in uterine malignant mixed müllerian tumor (MMMT) and to evaluate the expression of clinically relevant molecular markers...
  40. ncbi Laparoscopic port-site metastases: etiology and prevention
    Pedro T Ramirez
    Department of Gynecologic Oncology, Unit 440, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Gynecol Oncol 91:179-89. 2003
    ....
  41. ncbi Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA)
    Rodney J Hunter
    Division of Pharmacy, The University of Texas, M D Anderson Cancer Center, Houston, TX 77230, USA
    Cancer Treat Rev 35:69-78. 2009
    ..Under dosing patients with treatable or even curable disease to prevent toxicities could be costing the obese oncology patient population months to years of overall survival...
  42. ncbi Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel
    Sean Tedjarati
    Departments of Cancer Biology and Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2413-22. 2002
    ..Collectively, the data suggest that combining the optimal biological dose of PEG-IFN-alpha with paclitaxel may provide a novel and effective approach to the treatment of human ovarian carcinoma...
  43. ncbi Successful catheter-directed venous thrombolysis in phlegmasia cerulea dolens
    Celestine S Tung
    Department of Gynecologic Oncology, University of Texas Houston M D Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030, USA
    Gynecol Oncol 107:140-2. 2007
    ..Rare case reports have described the use of catheter-directed thrombolysis in the treatment of this condition. Prompt diagnosis and treatment initiation are important to prevent gangrene, amputation, and ultimately death...
  44. ncbi Wolffian duct tumors: case reports and review of the literature
    Pedro T Ramirez
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Gynecol Oncol 86:225-30. 2002
    ..Although generally considered a tumor of low malignant potential, these tumors can recur. Two cases are reported here...
  45. ncbi Groin recurrence in patients with vulvar cancer with negative nodes on superficial inguinal lymphadenectomy
    Mary E Gordinier
    Program in Women's Oncology, Brown University/Women and Infants' Hospital, Providence, RI, USA
    Gynecol Oncol 90:625-8. 2003
    ..SIL as performed on the patients in this study did not eliminate all sites of nodal metastasis...
  46. ncbi Trends among gynecologic oncology inpatient deaths: is end-of-life care improving?
    John L Dalrymple
    Division of Gynecologic Oncology, Medical Center, University of California at Davis, 4860 Y Street, Suite 2500, Sacramento, CA 95817, USA
    Gynecol Oncol 85:356-61. 2002
    ..The objective was to describe trends over time in key factors surrounding end-of-life care on a gynecologic oncology service at a tertiary cancer center...